It was encouraging to hear the news last week, that US-China Phase Two negotiations will be restarting. Negotiations last year were decidedly bumpy, and we should expect a similar passage in this round of talks. Donald Trump’s recent comments suggesting…
Read more...
Last Tuesday, the German Constitutional Court, ruled that the German government had failed to hold the European Central Bank (ECB) to account for some of its asset purchase programs, that are intended to support the EU’s economy across the void…
Read more...
The British people have reduced the impact of Covid-19 through a great act of social discipline but our discipline now looks to be starting to fray. More people are travelling or starting back to work. Maintaining the lockdown when we…
Read more...
Last week saw a number of significant economic results for Q1 being published. Several major companies released their results as did government agencies publish their GDP figures. The big tech companies such as Microsoft, Google, Facebook and Amazon all recorded…
Read more...
It is expected that Prime Minister Boris Johnson will return to No 10 today and take control of public policy amid growing cabinet concerns that the lockdown has gone on too long already. Senior cabinet ministers are voicing concerns that…
Read more...
The latest readings on the global economy are quite shocking and the challenges of fully lifting the lockdown soon mean that a swift V shape rebound in economic activity looks less likely. The latest health figures show that the pandemic…
Read more...
Last week the price of oil fell for the first time ever to below zero. The US focused West Texas Intermediate (WTI) oil price collapsed to -US$40.32 pb last Monday when traders had to pay to get rid of their…
Read more...
Angela Merkel stated ahead of Thursday’s critical EU summit that she believes that Germany should be ready to make far larger contributions to the EU budget and that extra funding should be provided in the spirit of solidarity but for…
Read more...
Gilead, the California-based biotech company has developed an anti-viral drug that some experts hope could stop the Covid-19 virus from replicating. The drug was originally developed for Ebola, but has never been approved. Gilead’s Remdesivir drug has shown early positive…
Read more...